Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
2018 ◽
Vol Volume 11
◽
pp. 8575-8587
◽
Yi-Long Wu
◽
Chong-Rui Xu
◽
Cheng-Ping Hu
◽
Jifeng Feng
◽
Shun Lu
◽
...
2014 ◽
Vol 85
(3)
◽
pp. 401-407
◽
Yi-Long Wu
◽
Shun Lu
◽
Ying Cheng
◽
Caicun Zhou
◽
Mengzhao Wang
◽
...
Y. Belaroussi
◽
S. Cousin
◽
M. Carton
◽
M. Lebitasy
◽
L. Laborde
◽
...
2020 ◽
Vol 9
(10)
◽
pp. 3328-3336
◽
Haiyan Xu
◽
Quan Zhang
◽
Li Liang
◽
Junling Li
◽
Zhefeng Liu
◽
...
2019 ◽
Vol 8
(8)
◽
pp. E11-E14
Teppei Yamaguchi
◽
Toyoaki Hida
2009 ◽
Vol 9
(4)
◽
pp. 425-435
◽
Marcello Tiseo
◽
Marco Bartolotti
◽
Francesco Gelsomino
◽
Andrea Ardizzoni
2010 ◽
Vol 67
(2)
◽
pp. 475-479
◽
Xin-Hua Xu
◽
Jin Su
◽
Xiang-Yang Fu
◽
Feng Xue
◽
Qiao Huang
◽
...
2003 ◽
Vol 39
(1)
◽
pp. 77-84
◽
J.M Vieitez
◽
M Valladares
◽
M Gracia
◽
M Gonzalez-Barón
◽
G Martı́n
◽
...
Nan Qiao
◽
Ralph Insinga
◽
Thomas Burke
◽
Gilberto Lopes
2018 ◽
Vol 9
(12)
◽
pp. 1716-1724
◽
Puyuan Xing
◽
Yuxin Mu
◽
Yan Wang
◽
Xuezhi Hao
◽
Yixiang Zhu
◽
...
Close
Export Citation Format
Close
Share Document
Close